Home › Hidradenitis Suppurativa › Arizona
Hidradenitis Suppurativa clinical trials in Arizona
7 studies for Hidradenitis Suppurativa are looking for participants at sites in Arizona.
Cities in Arizona
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Scottsdale Clinical Trials- Site Number : 8400006, Scottsdale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07225569Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Investigative Site US004, Phoenix
- Investigative Site US115, Tucson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06855498Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
- Saguaro Dermatology, Phoenix
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Sep 15, 2026 · NCT07049575Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- Medical Dermatology Specialists - Site Number: 8400019, Phoenix
- Mayo Clinic in Arizona - Scottsdale- Site Number : 8400014, Scottsdale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07170917Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- Medical Dermatology Specialists Phoenix, Phoenix
- Saguaro Dermatology, Phoenix
RecruitingPhase 2
Ages 12 to 17 · All sexes · Updated Aug 6, 2026 · NCT07213973A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
- Medical Dermatology Specialist, Phoenix
- Scottsdale Clinical Trials, Scottsdale
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 22, 2026 · NCT07384975A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
- Mayo Clinic, Scottsdale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 6, 2026 · NCT07244263From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.